share lag post guidanc due number factor
believ stock could continu lag given uncertainti post divestitur
upjohn around midyear assum pipelin deliv visibl post
analyst meet share could much stronger perform thu reiter
outperform rate pt
provid two set guidanc result neither reflect compani
report first set guidanc assum retain upjohn full
year consist typic detail guidanc second set guidanc assum
biopharma ex upjohn exist januari continu guid
mid year divestitur upjohn like spin split remain possibl
albeit less like upjohn reflect financi discontinu
busi two set guidanc impli anticip upjohn
contribut ep sinc upjohn like part six month
upjohn contribut ep therefor ep guidanc reflect
way report sale guidanc rang appear
lower ep estim year amount rang
ep estim reflect month upjohn
contribut impli ep
compound-annual-growth-rate reduct last-publish expect
also lower sale estim year amount rang
sale estim upjohn contribut
month albeit could prove conserv
impli sale compound-annual-growth-rate unchang last-publish
expect major reduct stem lower estim xejanz given
fy assum gross pm guidanc combin entiti
guidanc estim si lower
si guidanc vs estim guidanc vs
estim assum tax rate hold regardless upjohn spin
share count higher previou forecast given repurchas
told oper margin forecast vs previous
adjust dilut earn per share ep defin report
relat cost discontinu oper certain signific
pleas see page report import disclosur
outperform rate stock larg key solid dividend yield
compel valuat research product appear improv post
corpor reconfigur prospect driven high-valu biopharma busi
manag appear adept execut deliv transform
share garner above-averag multipl
upjohn divestitur mid
tafamidi rollout ttr cardiomyopathi
ibranc penelop data post
abrocitinib ph data atop
data adult phase ii data
everi earli stage product
launch achiev
acceler and/or adjuv trial
pipelin achiev greater expect
pfizer inc global biopharmaceut compani divers portfolio pharma product
cover area cardiovascular anti-infect anti-inflammatori oncolog
metabol diseas other also strong vaccin portfolio own gsk
consum plan divest upjohn busi
compani data cowen compani
salestotalgrosssg ar doper non- tax netcash share mm chg mm sl mm slsp op rate estim assum upjohn spun rather split number share remain unchang dividend reduc share count would reduc upjohn split dividend would chang cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
 eu lc ex develop emerg vaccin vaccin eu lc ex vaccin vaccin develop vaccin emerg vaccin vaccin vaccin eu lc ex vaccin vaccin develop vaccin emerg vaccin world-wide immunolog enbrel eu lc ex develop emerg total ex us eu lc ex develop emerg eu lc ex develop emerg eu lc ex develop emerg cowen
compani data cowen compani
 immunolog continu eu lc ex develop emerg inflamm immunolog inflamm immunolog eu lc ex inflamm immunolog inflammation/immunolog develop inflammation/immunolog emerg inflamm immunolog diseasebenefix eu lc ex develop emerg eu lc ex develop emerg eu lc ex develop emerg eu lc ex develop emerg eu lc ex develop emerg diseas diseas eu lc ex diseas diseas develop diseas emerg diseas cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
medicineeliqui donut hole posit patent expir eu lc ex fx eliqui develop emerg revenu record line begin box warn remov patent expir includ pedi exclusivitychampix/chantix eu lc ex fx champix/chantix warn relax patent expir septemb develop emerg smoke cessat pressur suicid concerns/label revisionspremarin eu lc ex fx premarin develop emerg world-wide dose eu lc ex develop emerg world-wide indic long bone fractur spinal fusiontoviaz eu lc ex fx toviaz develop emerg world-wide overact bladder eu diabet inhibitor mrk/pfe split approv eu coa-carboxylas inhib nash liver fibrosi fast w/lli chronic low back oa pain cancer pain safeti limit file low dose oa khk inhibitor non-alcohol steatohepat nash like hypertriglyceridemia non-alcohol steatohepat nash intern medicin intern medicin eu lc ex fx intern medicin intern medicin develop intern medicin emerg intern medicin world-wide intern medicin intern medicin eu lc ex fx total intern medicin intern medicin develop intern medicin emerg intern medicin world-wide biopharm group cowen
compani data cowen compani
 advanc breast cancer approv label bc set trial ibranc eu lc ex patent term extens pendingibr base paloma develop emerg inhibitor high risk earli adjuv breast cancer phase sutent tyrosin kinas inhibitor approv adjuv rcc patent expir eu lc ex fx sutent expir juli ema deni use adjuv rcc develop emerg gleevec-resist gist rcc gu gi xtandi eu lc ex fx xtandi develop emerg revenu gross profit split astella record line advanc nsclc small percent patient lung cancer patient xalkori eu lc ex fx xalkori develop emerg oral c-met inhibitor competit clipsbosulif eu lc ex fx bosulif develop emerg abl/src kinas inhibitor approv line cmlinlyta lung thyroid hepat melanoma glioblastoma liver keytruda xalkori rccinlyta eu lc ex fx inlyta develop emerg vegf tyrosin kinas braf inhib loe melanoma mek inhib loe melanoma braftovi/mektovi partner loe via array acquiisit close parp inhib apprvd us/eu brca-mut bc tnbc inhib approv nsclc phase penetr blood brain calicheamycin conjug r/r approv eu smo smoothen antagonist aml approv prioriti review/orphan eu md pan-her inhib egfr nsclc approv /eu previous tx advanc inhib merck kgaa mkted merkel cell bladder rcc dlbcl nsclc gastric urotheli adj scchn colon mcc io asset clinic gross profit cowen
compani data cowen compani
continu oncolog oncolog eu lc ex fx oncolog oncolog develop oncolog emerg oncolog world-wide retacrittot oncolog oncolog eu lc ex fx total oncolog oncolog develop oncolog emerg oncolog world-wide biopharm group grouphospitalsulperazon eu lc ex fx sulperazon develop emerg world-wide sulbactam/cefoperazon antibioticmedrol eu lc ex fx medrol develop emerg patent expir eu lc ex fx zithromax develop patent expir emerg spectrum antibiot declinevfend settlement gener enter market eu lc ex fx vfend expir develop emerg eu lc ex fx epipen develop emerg upjohn cowen
compani data cowen compani
continu zyvox expir eu lc ex fx zyvox expir -develop emerg infectionsfragmin eu lc ex fx fragmin develop emerg lmw heparin ucad hip abdom surg pat exp zosyn market new form patent exp eu lc ex fx zosyn exp develop emerg antibiot eu lc ex fx develop emerg multi-specialti specialti api supplieroth anti-infect anti-infect eu lc ex fx anti-infect anti-infect develop anti-infect emerg anti-infect world-wide hospit hospit eu lc ex fx hospit hospit develop hospit emerg hospit world-wide hospit hospit eu lc ex fx total hospit hospit develop hospit emerg hospit world-wide biopharm group cowen
compani data cowen compani
 recommend adult post capita june vote chang share decisionprevnar eu lc ex fx prevnar reimburs gain country-by-countri basisprevnar develop await reimbursementprevnar emerg valent pneumococc conjug vaccin valent valent developmentoth vaccin vaccin eu lc ex fx vaccin vaccin develop vaccin emerg vaccin trumenba difficil neisvac-c meningitec hibtitertot vaccin vaccin eu lc ex fx total vaccin vaccin develop vaccin emerg vaccin world-wide biopharm group immunolog enbrel eu lc ex fx enbrel launch lifmior enbrel dual brand yet launchedenbrel develop emerg total ex us arthriti right foreign mkt ex /canada patent expir eu xeljanz ra uc patent expir potenti month pedi exclusivityxeljanz eu lc ex fx xeljanz ra uc modifi releas tablet ra file patent expir develop emerg oral inhibitor ankylos spondyl new black box could clip useinflectra/remsima eu lc ex fx inflectra/remsima develop emerg eucrisa/staqui eu lc ex fx eucrisa/staqui chmp januari staquiseucrisa develop emerg topic inhibitor mild/moder atop dermat pedi/adult via anacor acq close previous estim peak sale jak inhibitor atop dermat phase breakthrough alopecia areata breakthrough ra ulcer coliti crohn diseas rheumatoid arthriti phase ii ibd phase ii rheumatoid arthriti phase psoriasi alopecia areata uc crohn vitiligo pa lupu phase ii ad psorasi beta fibroblast blocker inflammatori disord biolog phase psoriasi phase ii ulcer coliti phase blocker ulcer coliti biolog phase ii cowen
compani data cowen compani
 immunolog continu eu lc ex fx develop emerg inflamm immunolog inflamm immunolog eu lc ex fx total inflamm immunolog inflammation/immunolog develop inflammation/immunolog emerg inflamm immunolog biopharm group diseasebenefix eu lc ex fx benefix develop emerg competit pressuresgenotropin eu lc ex fx genotropin develop emerg hormon children adult refacto/xyntha eu lc ex fx refacto/xyntha develop emerg xyntha albumin free competit pressuressomavert eu lc ex fx somavert develop emerg growth hormon antagonist acromegali via sensusvyndaqel/vyndamax approv polyneuropathi file fast track orphan vyndaqel/vyndamax eu lc ex fx vyndaqel/vyndamax approv ttr-cardiomyopathi review orphan vyndaqel/vyndamax develop emerg meglumin ttr dissoci inhibitorfidanacogen therapy/coagul factor ix hemophilia biolog breakthru/orphan /eu phase hgh agonist gh defici biolog orphan statu us/eu piii adult piii aav-fviii hemophilia biolog fast track/orphan us/eu phase tissu factor pathway inhibitor tfpi hemophilia biolog orphan us/eu phase mitogen-activ protein kinas dilat cardiomyopathi due mutat biolog phase focal segment glomerulosclerosi fsg biolog phase iiother diseas diseas eu lc ex fx diseas diseas develop diseas emerg diseas cowen
compani data cowen compani
diseas continu total diseas diseas eu lc ex fx total diseas diseas develop diseas emerg diseas biopharm group eu lc ex fx biopharma develop emerg total pfizer guidanc target revenu approxim established/upjohn pedi exclus expir eu lc ex fx lyrica gad patent expir pain patent expir lyrica develop established/upjohn emerg established/upjohn monotx central neuropath pain due spinal injuri post op pain cr qd bid dose lipitor gener launch eu lc ex fx lipitor basic patent expir pedi extensionlipitor develop basic patent expir emerg patent expir juli china strong formulari posit lost cholesterol reduct market growth anticipatednorvasc eu lc ex fx norvasc develop emerg competit erod franchis temper emerg rowcelebrex patent expir multipl gener launchedcelebrex eu lc ex fx celebrex expir develop emerg launch ciali gener includ canada move eh eu lc ex fx viagra expir develop emerg treatment cowen
compani data cowen compani
continu effexor gener competit post eu lc ex fx effexor expir major marketseffexor develop file withdrawneffexor emerg depress market grow modestlyzoloft competit pressureszoloft eu lc ex fx zoloft expir februari develop japan possibl zoloft emerg expir eu lc ex fx xalatan develop emerg glaucoma xalcom europeepipen eu lc ex fx epipen develop emerg biopharm upjohn upjohn eu lc ex fx upjohn upjohn develop upjohn emerg upjohn upjohn upjohn eu lc ex fx total upjohn upjohn develop upjohn emerg upjohn combin close via spin split receiv cash healthcar businessconsum healthcar busi healthcar busi eu lc ex fx consum healthcar busi healthcar busi develop healthcar busi emerg healthcar busi jv gsk close gsk own de-merg year post quarter lag report month incom given month lag fgn bookspfiz total total eu lc ex fx pfizer total total develop total emerg total cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ success pipelin product patent expir greater
expect impact ep success streamlin and/or separ busi
structur outcom potenti
